Rucaparib phosphate (AG014699; PF01367338)

Description: Rucaparib (formerly AG-014699 or PF-01367338; trade name: Rubraca) is a potent, tricyclic indole based, and orally bioavailable inhibitor of PARP (poly(ADP-Ribose) polymerase) with potential anticancer activity. It has a Ki of 1.4 nM for inhibiting PARP1 in a cell-free assays. In December 2016, Rucaparib was approved by the US FDA to treat women with a certain type of ovarian cancer. Rucaparib selectively binds to PARP1 and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy.

References: Mol Cancer Ther. 2007 Mar; 6(3):945-56; Br J Cancer. 2010 Nov 9; 103(10):1588-96.

Related CAS: 283173-50-2 (free base); 1859053-21-6 (Rucaparib camsylate); 459868-92-9 (phosphate) ;

AG014699; PF-01367338; AG 014699; PF 01367338; AG-014699, PF01367338; AG-14447; AG 14447; AG14447; Trade name: Rubraca; Rucaparib

Chemical Name: 8-fluoro-2-(4-((methylamino)methyl)phenyl)-4, 5-dihydro-1H-azepino[5, 4, 3-cd]indol-6(3H)-one phosphate

InChi Key: FCCGJTKEKXUBFZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H18FN3O.H3O4P/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15; 1-5(2, 3)4/h2-5, 8-9, 21, 23H, 6-7, 10H2, 1H3, (H, 22, 24); (H3, 1, 2, 3, 4)

SMILES Code: O=C1NCCC2=C(C3=CC=C(CNC)C=C3)NC4=C2C1=CC(F)=C4.O=P(O)(O)O